SF1729

Summary

A Minnesota bill proposing modifications to cannabinoid-derived hemp sales provisions has had its chief author stricken and is now listed under a co-author, indicating early-stage legislative activity. Changes to cannabinoid sales provisions could affect licensing, product eligibility, and market access for hemp retailers and processors in Minnesota.

More Minnesota Cannabis Bills

• SF4401Omnibus Cannabis billPassed
• SF4957Registered designated caregivers provisions modifications and increasing patient and cannabis plant limits expansion provisionIntroduced
• HF3615Cannabis laboratory testing requirements extended.Passed
• SF4877Cannabis license application periods and issuance modificationIntroduced
• SF4871Remediated cannabis product definitionIntroduced
• SF4876Cannabis microbusiness outdoor cultivation limit increaseIntroduced
• HF4733Remediated cannabis product defined, and cannabis business required to disclose information related to remediated cannabis products.Introduced
• SF4875Medical cannabis endorsement requirements modificationIntroduced
• HF4688Cannabis license holders allowed to transport products to testing facilities.Introduced
• HF4577Psilocybin therapeutic use program established; protections for registered patients, registered suppliers, registered facilitators, and health care practitioners established; civil actions authorized; advisory committee established; and money appropriated.Introduced
• HF4570Cannabis microbusiness outdoor cultivation limit increased.Introduced
• SF4542Cannabis event provisions modificationIntroduced